Browse

DA-6034, a derivative of flavonoid, prevents and ameliorates dextran sulfate sodium-induced colitis and inhibits colon carcinogenesis

Cited 24 time in Web of Science Cited 23 time in Scopus
Authors
Nam, Su Youn; Kim, Joo Sung; Kim, Jung Mogg; Lee, Jong Yeul; Kim, Nayoung; Jung, Hyun Chae; Song, In Sung
Issue Date
2008-01-29
Publisher
Society for Experimental Biology and Medicine
Citation
Exp Biol Med (Maywood) 233:180-191, 2008
Keywords
Acute DiseaseAnimalsApoptosis/drug effectsBody Weight/drug effectsCell Transformation, NeoplasticColitis/*chemically induced/complications/enzymology/*prevention & controlColonic Neoplasms/complications/pathology/*prevention & controlCyclooxygenase 2/metabolismDextran Sulfate/*pharmacologyDisease Models, AnimalFlavonoids/*pharmacologyI-kappa B Kinase/metabolismKi-67 Antigen/metabolismMaleMiceMice, Inbred C57BLPhosphorylation/drug effects
Abstract
Previously, we have shown that DA-6034, a synthetic derivative of flavonoid eupatilin, inhibited NF-kappaB activation in colon epithelial cells and prevented trinitrobenzene sulfonic acid-induced rat colitis. The aim of this study was to investigate the preventive and therapeutic effect of DA-6034 on dextran sulfate sodium (DSS)-induced colitis and on inflammation-related cancer. C57BL/6 mice were given 4% DSS for 5 days with and without DA-6034 in the acute preventive model. In the acute therapeutic model, mice were given 4% DSS for 5 days followed by rectal administration of DA-6034. Colitis was quantified by body weight, disease activity index (DAI), colon length, and histology. In the inflammation-related cancer model, mice were given a single intraperitoneal injection of azoxymethane, then three cycles of 2% DSS for 5 days, then 2 weeks of free water consumption. Apoptosis was determined by in situ terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling assay, and the expression of Ki-67, phospho-kappaB kinase alpha (IKKalpha), and COX-2 were evaluated by immunohistochemistry. In both the acute preventive and acute therapeutic models, DA-6034 significantly attenuated DSS-induced weight loss, an increase in DAI, and a shortening of colon length. DA-6034-treated mice maintained crypt architecture and revealed a scanty infiltration of inflammatory cells in both the preventive and therapeutic models. In the inflammation-related cancer model, DA-6034 reduced the number of colon tumors and ameliorated weight loss and shortening of colon length. DA-6034 strongly enhanced apoptosis and inhibited the expression of COX-2 and phospho-IKKalpha in inflammation-related colon cancer models. Our results suggest that DA-6034 prevents acute murine colitis and inhibits inflammation-related colon carcinogenesis. DA-6034 could be a potential therapeutic agent for inflammatory bowel disease.
ISSN
1535-3702 (Print)
Language
English
URI
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18222973

http://hdl.handle.net/10371/23416
DOI
https://doi.org/10.3181/0707-RM-186
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Program in Clinical Pharmacology (협동과정-임상약리학전공)Journal Papers (저널논문_협동과정-임상약리학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse